开云app官网登录入口网页版-官方正版

#lenvatinib#

21篇内容 | 1332人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1464258, encodeId=f8801464258db, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标, objectType=article, longId=299284, objectId=0f55299284f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f55299284f7, replyNumber=0, likeNumber=62, createdTime=2022-02-22, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f55299284f7, moduleTitle=Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0f55299284f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464257, encodeId=1807146425e0e, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Liver Cancer：Lenvatinib（仑伐替尼）在肝细胞癌中的真实世界疗效:一项回顾性多中心研究(ELEVATOR), objectType=article, longId=294116, objectId=bee2294116f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee2294116f4, replyNumber=0, likeNumber=79, createdTime=2022-01-18, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee2294116f4, moduleTitle=Liver Cancer：Lenvatinib（仑伐替尼）在肝细胞癌中的真实世界疗效:一项回顾性多中心研究(ELEVATOR), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bee2294116f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464256, encodeId=4b5c1464256c2, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性, objectType=article, longId=292159, objectId=2e392921592b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e392921592b, replyNumber=0, likeNumber=79, createdTime=2021-12-19, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e392921592b, moduleTitle=Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2e392921592b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464255, encodeId=8b6514642551b, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, objectType=article, longId=221179, objectId=74cf2211e969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cf2211e969, replyNumber=0, likeNumber=69, createdTime=2021-11-29, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cf2211e969, moduleTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74cf2211e969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464254, encodeId=231d146425470, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, objectType=article, longId=220495, objectId=dbd22204957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd22204957c, replyNumber=0, likeNumber=63, createdTime=2021-11-18, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd22204957c, moduleTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbd22204957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464253, encodeId=e0bb1464253c8, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, objectType=article, longId=219316, objectId=14432193166f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14432193166f, replyNumber=0, likeNumber=68, createdTime=2021-10-28, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14432193166f, moduleTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=14432193166f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464252, encodeId=c170146425278, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, objectType=article, longId=217963, objectId=568c21e96338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=568c21e96338, replyNumber=0, likeNumber=87, createdTime=2021-10-02, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=568c21e96338, moduleTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=568c21e96338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464251, encodeId=7a4a1464251b1, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=European Urology：Lenvatinib联合依维莫司治疗晚期肾非透明细胞癌，客观缓解率达26%！, objectType=article, longId=215161, objectId=574121516111, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574121516111, replyNumber=0, likeNumber=47, createdTime=2021-08-03, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574121516111, moduleTitle=European Urology：Lenvatinib联合依维莫司治疗晚期肾非透明细胞癌，客观缓解率达26%！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=574121516111)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464250, encodeId=1c111464250bc, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, objectType=article, longId=214268, objectId=9fbc2142681c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fbc2142681c, replyNumber=0, likeNumber=70, createdTime=2021-07-17, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fbc2142681c, moduleTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9fbc2142681c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464249, encodeId=cfa61464249b9, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, objectType=article, longId=211561, objectId=4f32211561f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f32211561f9, replyNumber=0, likeNumber=67, createdTime=2021-05-21, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f32211561f9, moduleTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4f32211561f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464248, encodeId=edc414642482e, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Eur Urol：Lenvatinib+Everolimus治疗晚期非透明细胞肾细胞癌患者的单臂、多中心和2期研究, objectType=article, longId=211527, objectId=c72c21152e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c72c21152e19, replyNumber=0, likeNumber=71, createdTime=2021-05-20, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c72c21152e19, moduleTitle=Eur Urol：Lenvatinib+Everolimus治疗晚期非透明细胞肾细胞癌患者的单臂、多中心和2期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c72c21152e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464247, encodeId=9e1f146424e00, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌, objectType=article, longId=203136, objectId=a3c920313621, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c920313621, replyNumber=0, likeNumber=130, createdTime=2020-11-10, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c920313621, moduleTitle=IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a3c920313621)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464246, encodeId=3180146424643, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果, objectType=article, longId=190523, objectId=37e61905231f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37e61905231f, replyNumber=0, likeNumber=0, createdTime=2020-03-22, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37e61905231f, moduleTitle=lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=37e61905231f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464245, encodeId=d9171464245f0, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=EUR J Cancer：Lenvatinib治疗甲状腺癌临床试验中的生物标志物的探索性分析, objectType=article, longId=125183, objectId=9a0012518309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a0012518309, replyNumber=0, likeNumber=52, createdTime=2018-01-01, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a0012518309, moduleTitle=EUR J Cancer：Lenvatinib治疗甲状腺癌临床试验中的生物标志物的探索性分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9a0012518309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464244, encodeId=4ced146424429, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=J CLIN ONCOL：III期选择性试验中年龄对lenvatinib治疗放射性碘难治性分化型甲状腺癌疗效和安全性的影响, objectType=article, longId=102204, objectId=ee7a1022043f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7a1022043f, replyNumber=0, likeNumber=53, createdTime=2017-06-18, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7a1022043f, moduleTitle=J CLIN ONCOL：III期选择性试验中年龄对lenvatinib治疗放射性碘难治性分化型甲状腺癌疗效和安全性的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ee7a1022043f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464243, encodeId=a286146424359, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, objectType=article, longId=79539, objectId=ef32e9539e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef32e9539e8, replyNumber=0, likeNumber=45, createdTime=2016-10-10, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef32e9539e8, moduleTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ef32e9539e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464242, encodeId=f81c1464242d7, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=J Clin Endocrinol Metab：LEnvatinib治疗RR-DTC的肿瘤大小变化特征, objectType=article, longId=75861, objectId=c19ee586130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c19ee586130, replyNumber=0, likeNumber=45, createdTime=2016-08-26, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c19ee586130, moduleTitle=J Clin Endocrinol Metab：LEnvatinib治疗RR-DTC的肿瘤大小变化特征, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c19ee586130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464241, encodeId=9c7814642411d, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌, objectType=article, longId=68497, objectId=52236849e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52236849e07, replyNumber=0, likeNumber=64, createdTime=2016-05-19, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52236849e07, moduleTitle=FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=52236849e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464240, encodeId=836914642400d, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=Lancet Oncol：Lenvatinib加依维莫司和lenvatinib单药治疗转移性肾细胞癌效果好, objectType=article, longId=57366, objectId=2de45e3662c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2de45e3662c, replyNumber=0, likeNumber=56, createdTime=2015-10-18, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2de45e3662c, moduleTitle=Lancet Oncol：Lenvatinib加依维莫司和lenvatinib单药治疗转移性肾细胞癌效果好, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2de45e3662c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464239, encodeId=1fc5146423925, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, objectTitle=NEJM：Lenvatinib有望用于放射性碘难治性甲状腺癌治疗, objectType=article, longId=47049, objectId=71304e049a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71304e049a4, replyNumber=0, likeNumber=56, createdTime=2015-02-14, rootId=0, userName=tastas, userId=0b506628012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71304e049a4, moduleTitle=NEJM：Lenvatinib有望用于放射性碘难治性甲状腺癌治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=71304e049a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

lenvatinib

2020-05-29

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标

2022-02-22

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Liver Cancer：Lenvatinib（仑伐替尼）在肝细胞癌中的真实世界疗效:一项回顾性多中心研究(ELEVATOR)

2022-01-18

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性

2021-12-19

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究

2021-11-29

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性

2021-11-18

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析

2021-10-28

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效

2021-10-02

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

European Urology：Lenvatinib联合依维莫司治疗晚期肾非透明细胞癌，客观缓解率达26%！

2021-08-03

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究

2021-07-17

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择

2021-05-21

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Eur Urol：Lenvatinib+Everolimus治疗晚期非透明细胞肾细胞癌患者的单臂、多中心和2期研究

2021-05-20

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌

2020-11-10

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果

2020-03-22

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

EUR J Cancer：Lenvatinib治疗甲状腺癌临床试验中的生物标志物的探索性分析

2018-01-01

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

J CLIN ONCOL：III期选择性试验中年龄对lenvatinib治疗放射性碘难治性分化型甲状腺癌疗效和安全性的影响

2017-06-18

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发

2016-10-10

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

J Clin Endocrinol Metab：LEnvatinib治疗RR-DTC的肿瘤大小变化特征

2016-08-26

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌

2016-05-19

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

Lancet Oncol：Lenvatinib加依维莫司和lenvatinib单药治疗转移性肾细胞癌效果好

2015-10-18

tastas (审核中...)

前往app查看评论内容

#lenvatinib#

NEJM：Lenvatinib有望用于放射性碘难治性甲状腺癌治疗

2015-02-14

科室
- - 订阅+
  - 更多科室
工具
服务